VIENNA—For women with premenopausal breast cancer the benefits of using the most adjuvant endocrine treatment needs to be weighed against additional side effects—according to Marco Colleoni MD from the European Institute of Oncology in Milan. After his talk at the St Gallen breast cancer conference he discussed criteria for individualizing optimal endocrine adjuvant treatments with Oncology Times reporter Sarah Maxwell.
You may also like...
Tumor Microenvironment: Tumor Infiltrating Lymphocyte Score Predicts Breast Cancer Outcome 27 Mar, 2015 Gastrointestinal Cancers: Progress with Targeted Therapies 27 Jan, 2008 New Strategies for Preventing ER-Negative Breast Cancer 23 Mar, 2015 New Drug for Patients with EGFR-TKI-resistant Advanced Non-Small Cell Lung Cancer 27 Apr, 2015
- Previous story Genetic Tests for Breast Cancer Late Recurrence Risk—Not Yet Ready for Prime Time
- Next story Deep Genomic Profiling in Breast Cancer Promises to Improve Outcomes
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014